Weight gain, improvement in metabolic profile, and CD4 count with insulin administration in an AIDS patient.
Malnutrition with muscle wasting, weight loss, and decreased immunogenicity is a hallmark of Acquired Immune Deficiency Syndrome (AIDS). Several anabolic agents have been utilized for retarding or preventing progressive wasting with limited success. However, insulin, with its most effective anabolic properties, has not been tried in an attempt to prevent or reverse cachexia in AIDS or any other wasting disorders. We report here the effect of using subcutaneous (s.c.) daily administration of insulin 0.3 U/kg (BW) for 6 months in a subject with AIDS. We noted a marked weight gain, improvement in metabolic profiles, that is, lowering of triglyceride, liver enzymes, glycohemoglobin concentrations, as well as 24-hour urinary excretion of urea nitrogen, protein, and creatinine suggestive of positive energy balance. Simultaneously, a marked rise in CD4 counts and an improvement in the thyroid hormone profile were also noted. A deterioration in these parameters occurred during the period of insulin withdrawal following completion of the study protocol. Resumption of insulin administration, on patient's request, once again resulted in the marked improvement similar to that noted during the study period. No adverse effects, including hypoglycemic episodes, were noted during either phase of insulin administration. The possibility that insulin administration may improve the wasting associated with AIDS may warrant further evaluation.
Kabadi
U M
UM
VA Medical Center, Phoenix, Arizona, USA. Udaya-kabadi@uiowa.edu
Reust
C S
CS
Kabadi
M U
MU
D001786:Blood Glucose / Q000032:analysis / Q000187:drug effects; D018791:CD4 Lymphocyte Count; D003404:Creatinine / Q000652:urine; D004734:Energy Metabolism; D019247:HIV Wasting Syndrome / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism*; D006454:Hemoglobins / Q000032:analysis / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D007328:Insulin / Q000494:pharmacology / Q000627:therapeutic use*; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D013963:Thyroid Hormones / Q000097:blood; D014280:Triglycerides / Q000097:blood; D014508:Urea / Q000652:urine; D015430:Weight Gain / Q000187:drug effects*
D001786:Blood Glucose; D006454:Hemoglobins; D007004:Hypoglycemic Agents; D007328:Insulin; D013963:Thyroid Hormones; D014280:Triglycerides; D014508:Urea; D003404:Creatinine